Quality Recruiting. Established Experts.

Metabolic Pharmacology Leader

Our client is a biopharmaceutical company, pioneering the development of a novel class of therapeutics. They have asked us to assist them in their search for a Metabolic Pharmacology Leader.

The incumbent will establish and leverage mammalian in vivo model systems, in order to address key questions about the efficacy of their engineered probiotics operating within the gastrointestinal system and the microbiome as an integral point for modulation of systemic metabolic disease.

Major tasks and responsibilities will include:

Works with internal teams, external partners and experts to implement novel experimental systems to trace and characterize key metabolites and nutrients in the body.

Assists in the development of synthetic biotics as therapies for inborn errors of metabolism.

Establishes a new therapeutic modality that is leveraging the gastrointestinal tract and the strengths of synthetic biology towards the treatment of rare and intractable human diseases.

Experience in research and development for gastrointestinal physiology and metabolic disease indications highly preferred.

Microbial or biotherapeutics experience a plus.

Requires expertise in working with complex animal models in therapeutic areas such as inborn errors of metabolism, rare disease, metabolic diseases or liver diseases.

Must have experience developing in vivo models and their application to therapeutic discovery and development.

Strong analytical and problem solving capabilities, as well as, solid oral and written communication skills.

Requires a strong publication track record.

Must have experience working in cross functional multidisciplinary teams.

If interested, please email your resume as a Word attachment to us, reference 3929. No calls or faxes, please. Include your daytime phone number and we will contact you confidentially or reply to your email.

Fairway Consulting Group is included in Hunt Scanlon’s list of Top 50 Healthcare & Life Sciences Search Firms.